Article

<i>In vivo</i> efficacy of fidaxomicin against <i>rpoB</i> mutant <i>Clostridioides difficile</i> infection

2025-04-18

Abstract excerpt

<h4>ABSTRACT</h4> <h4>Objectives</h4> Clostridioides difficile infection (CDI) is a well-known healthcare-associated diarrheal disease. Fidaxomicin, a key antibiotic used to treat CDI, targets rpoB . However, some clinical isolates have mutations in rpoB , which reduces their susceptibility to this antibiotic. In this study, the effects of rpoB mutations on the virulence of C. difficile and efficacy of fidax...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3febd3a4-bf75-50b7-8733-1e46da0c1408
DOI: 10.1101/2025.04.17.649461

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

<i>In vivo</i> efficacy of fidaxomicin against <i>rpoB</i> mutant <i>Clostridioides difficile</i> infectionDOI 10.1101/2025.04.17.649461Read

Characterization of a clinical Clostridioides difficile isolate with markedly reduced fidaxomicin susceptibility and a V1143D mutation in rpoBSemantic proximity Read

Antibacterials Developed to Target a Single Organism: Mechanisms and Frequencies of Reduced Susceptibility to the Novel Anti-Clostridium difficile Compounds Fidaxomicin and LFF571.Semantic proximity Read

Biology of <i>Clostridium difficile</i>: Implications for Epidemiology and DiagnosisSemantic proximity Read

<i>In Vitro</i> Activity of Fidaxomicin (OPT-80) Tested against Contemporary Clinical Isolates of <i>Staphylococcus</i> spp. and <i>Enterococcus</i> sppSemantic proximity Read

Emergence and Spread of Clostridioides difficile Isolates With Reduced Fidaxomicin Susceptibility in an Acute Care Hospital.Semantic proximity Read

Clinical and pharmacoeconomic evaluation of fidaxomicin in patients over 65 years of age and immunocompromised patients with recurrent and refractory Clostridioides difficile infectionSemantic proximity Read

In vivo emergence of a still uncommon resistance to fidaxomicin in the urgent antimicrobial resistance threat Clostridioides difficileSemantic proximity Read

Basis of narrow-spectrum activity of fidaxomicin on gut pathogen <i>Clostridioides difficile</i>Semantic proximity Read

Microbiome impact of ibezapolstat and other <i>Clostridioides difficile</i> infection relevant antibiotics using humanized miceSemantic proximity Read

In vitro selection, via serial passage, of Clostridium difficile mutants with reduced susceptibility to fidaxomicin or vancomycin.Semantic proximity Read

Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.Semantic proximity Read

Systems biology evaluation of refractory Clostridioides difficile infection including multiple failures of fecal microbiota transplantation.Semantic proximity Read